Trial initiated to compare insulin degludec/liraglutide, insulin degludec, and liraglutide efficacy in Chinese T2DM patients.

Type 2 Diabetes Mellitus (T2DM) remains a significant global health challenge, particularly in Asia, with many patients struggling to achieve optimal glycemic control despite existing oral antidiabetic drugs (OADs). Inadequate control can lead to severe microvascular and macrovascular complications. Current treatment paradigms often involve escalating therapy to include GLP-1 receptor agonists or basal insulin. However, combining these agents can offer synergistic benefits, potentially improving HbA1c reduction while mitigating side effects like hypoglycemia or weight gain. This trial addresses the need for effective, well-tolerated combination therapies specifically tailored for the Chinese T2DM population, where distinct genetic and lifestyle factors may influence treatment response.

This randomized, controlled clinical trial is recruiting Chinese subjects diagnosed with Type 2 Diabetes Mellitus who exhibit inadequate glycemic control despite current treatment with oral antidiabetic drugs. Participants will be assigned to one of three treatment arms: insulin degludec/liraglutide fixed-ratio combination, insulin degludec monotherapy, or liraglutide monotherapy. The primary endpoint for this study is the change in Glycosylated Haemoglobin (HbA1c) from baseline, aiming to confirm the superior efficacy of the combination therapy in achieving robust glycemic control. The trial design also implicitly includes safety assessments, as indicated by similar trial descriptions.